Halozyme (HALO) Boosted by ENHANZE Launches and Analyst Upgrade

Core Insights - Halozyme Therapeutics, Inc. (NASDAQ:HALO) is recognized as one of the top new stocks to buy in Ray Dalio's portfolio, with TD Cowen raising its price target from $79 to $90 while maintaining a Buy rating, indicating strong performance and positive outlook for the company [1] Group 1: Financial Performance and Projections - TD Cowen believes that forecasts regarding ongoing ENHANZE launches are overly conservative, suggesting that additional resources in late-stage development will likely enhance the momentum of the company's subcutaneous medication delivery technology [2] - The company is expected to improve its multi-year outlook following strong performance in recent quarters [1] Group 2: Strategic Partnerships - Halozyme Therapeutics has entered into a global collaboration and exclusive licensing agreement with Takeda for its ENHANZE drug delivery technology, which includes an upfront payment and potential future milestone payments from Takeda [3] - The agreement stipulates that Halozyme will receive royalties ranging from low to mid single digits on sales of products that include vedolizumab in conjunction with ENHANZE [3] Group 3: Company Overview - Halozyme Therapeutics is a biopharmaceutical technology platform company focused on developing, manufacturing, and commercializing drug-device combination products utilizing advanced auto-injector technology [4]